Direct answer
There is no FDA-approved Epitalon dose chart for longevity or sleep
Epitalon, also spelled Epithalon, is an investigational tetrapeptide discussed around pineal signaling, circadian rhythms, telomerase, and healthy-aging theories. It does not have an FDA-approved finished drug label for insomnia, anti-aging, telomere extension, cancer prevention, diabetes, weight loss, or lifespan extension. Online charts often present exact amounts, course lengths, timing, and repeat cycles as if they were standardized clinical care. Those numbers cannot establish that the marketed product contains the claimed ingredient, that a route is appropriate, or that the plan is safe for a particular person.
- A commonly cited Epithalon paper reported telomerase activity in cultured human cells; it was not a dosing trial showing longer or healthier lives in patients.
- A cited melatonin-and-cortisol study involved aging monkeys, not a human insomnia trial that validates an online nighttime protocol.
- Compounded medications, when lawfully prescribed for an individual patient, are not FDA-approved finished drug products and should not be advertised as approved Epitalon therapy.
Evidence limits
Mechanism diagrams cannot supply the missing clinical dose evidence
A dose should be tied to a defined product, route, population, outcome, and safety dataset. Epitalon marketing frequently moves from cell telomerase findings, animal circadian research, or broad “bioregulator” language to precise consumer schedules without the clinical steps in between. A biological mechanism does not prove that a marketed vial improves sleep, reverses aging, changes human telomeres safely, or lowers disease risk. It also does not reveal how long-term exposure, repeated courses, impurities, formulation differences, or combinations affect risk.
- Cell, animal, biomarker, and testimonial evidence should not be converted into human dose calculators or guaranteed outcomes.
- The spelling “Epitalon,” “Epithalon,” “Epithalamin,” or “pineal peptide” does not prove that products have the same composition or evidence.
- A clinician should investigate persistent insomnia, fatigue, mood change, weight change, weakness, or cognitive symptoms rather than assuming they are an Epitalon deficiency.
Safety review
Uncertain safety is a reason for more screening—not a reason to experiment
Limited clinical evidence means a public chart cannot reliably predict common adverse effects, rare reactions, long-term effects, or risk in people with cancer history, pregnancy, breastfeeding, endocrine disease, psychiatric conditions, kidney or liver disease, immune conditions, sleep disorders, or multiple medicines. Product quality adds a separate layer: concentration, sterility, excipients, storage, and labeling may differ across products. New or severe symptoms should be evaluated medically rather than managed by changing an online cycle.
- Review all prescriptions, over-the-counter medicines, hormones, sleep products, stimulants, alcohol, cannabis, and supplements before considering an investigational peptide.
- Ask how allergies, injection or formulation reactions, sleep or mood changes, persistent headache, fainting, breathing difficulty, infection signs, or other concerning symptoms will be handled.
- Do not combine Epitalon with melatonin, sedatives, stimulants, NAD+, rapamycin, metformin, hormones, GLP-1 medicines, or other peptides from a copied longevity stack.
FDA July watch
The July 2026 PCAC agenda does not approve an Epitalon dose or product
The Federal Register notice schedules an FDA Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026, and FDA materials list Epitalon free base and acetate for committee discussion in a section 503A bulk-drug-substance context. As of this page’s Pacific-time review date, the meeting is still in the future. An agenda item is not FDA approval, a finished-drug label, proof of effectiveness, a patient dosing recommendation, or permission for research-chemical sellers to market Epitalon for human use. PCAC recommendations are advisory; FDA makes final determinations after considering committee input and its own review.
- Treat “FDA reviewed,” “FDA approved in July,” “PCAC-approved protocol,” and “soon legal everywhere” as misleading unless a current official FDA source supports the exact claim.
- The committee process does not validate seller dose charts, injection instructions, cycling calendars, or disease and longevity claims.
- Patients should distinguish FDA approval, off-label prescribing, individualized compounding, clinical investigation, and research-use sales.
Seller and telehealth quality
Legitimate care requires more than a checkout form and certificate of analysis
A certificate of analysis, lab screenshot, influencer testimonial, or “doctor formulated” badge does not replace diagnosis, a valid prescription, licensed pharmacy dispensing, patient-specific labeling, medication reconciliation, or follow-up. A responsible clinician should explain why Epitalon is being considered despite limited evidence, what better-studied alternatives fit the goal, how the exact product is sourced, how response and adverse effects will be assessed, and what would trigger stopping or referral.
- Avoid no-prescription checkout, bulk vials, research-use products promoted for people, copied reconstitution instructions, hidden pharmacy identity, and crypto-only or marketplace sales.
- Avoid guaranteed sleep, telomere, anti-aging, cancer-prevention, biological-age, or lifespan claims and before-and-after biomarker promises.
- Ask for the prescriber’s license, dispensing pharmacy, ingredient and route, prescription label, storage and beyond-use information, adverse-event contact, follow-up cadence, and total cost.